Jocelyn Widjaja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jocelyn Widjaja has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Frank M. Gao
Department of Endocrinology (J.M.C., F.M.G., I.J.H.L., J.H.N.C.L., S.G.), Eastern Health, Box Hill, Victoria, Australia
1 shared publication- Ignatius J.H. Lee
Department of Endocrinology (J.M.C., F.M.G., I.J.H.L., J.H.N.C.L., S.G.), Eastern Health, Box Hill, Victoria, Australia
1 shared publication Jordan H.N.C. Lai
Department of Endocrinology (J.M.C., F.M.G., I.J.H.L., J.H.N.C.L., S.G.), Eastern Health, Box Hill, Victoria, Australia
1 shared publication- Josephine McCarthy
Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia (J.M.C., J.W., T.G.P., J.Y.).
1 shared publication Julia Harrison
Monash University, Clayton, Vic, Australia
1 shared publicationJun Yang
Monash University, Clayton, Vic, Australia
1 shared publication
Latest Publications
- 1 February 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (2) , 493-498
Testing for Primary Aldosteronism Underutilized Following Stroke: A Multicenter Cohort Study
BACKGROUND: Primary aldosteronism, the most common endocrine cause of hypertension, is associated with an increased risk of stroke compared with essential hypertension. Targeted treatment with mineralocorticoid receptor antagonists, or surgical resection of an aldosterone-producing adrenal adenoma, can effectively reduce blood pressure and mitigate cardiovascular risk. However, despite being a highly modifiable cardiovascular risk factor, primary aldosteronism is grossly underdiagnosed, even in high-risk populations. METHODS: We conducted a multicenter retrospective cohort study to assess the frequency of primary aldosteronism testing among patients admitted between January 2019 to January 2020 with stroke or transient ischemic attack. Data, including blood pressure, antihypertensive medication use, serum potassium, and adrenal imaging, were collected from the medical records of patients admitted for stroke or transient ischemic attack at 2 large tertiary hospitals in Victoria, Australia. RESULTS: Among 400 patients (mean age, 73.9±13.4 years; 42.1% female), 30% (n=120) had a clinical indication for primary aldosteronism testing, yet only 2% (n=8) were tested. CONCLUSIONS: These findings highlight a missed opportunity to identify a treatable cause of hypertension in patients at high risk of recurrent cerebrovascular events. Routine testing for primary aldosteronism in stroke care pathways may improve long-term outcomes through targeted intervention.
- 1 February 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (2) , 493-498
Testing for Primary Aldosteronism Underutilized Following Stroke: A Multicenter Cohort Study
BACKGROUND: Primary aldosteronism, the most common endocrine cause of hypertension, is associated with an increased risk of stroke compared with essential hypertension. Targeted treatment with mineralocorticoid receptor antagonists, or surgical resection of an aldosterone-producing adrenal adenoma, can effectively reduce blood pressure and mitigate cardiovascular risk. However, despite being a highly modifiable cardiovascular risk factor, primary aldosteronism is grossly underdiagnosed, even in high-risk populations. METHODS: We conducted a multicenter retrospective cohort study to assess the frequency of primary aldosteronism testing among patients admitted between January 2019 to January 2020 with stroke or transient ischemic attack. Data, including blood pressure, antihypertensive medication use, serum potassium, and adrenal imaging, were collected from the medical records of patients admitted for stroke or transient ischemic attack at 2 large tertiary hospitals in Victoria, Australia. RESULTS: Among 400 patients (mean age, 73.9±13.4 years; 42.1% female), 30% (n=120) had a clinical indication for primary aldosteronism testing, yet only 2% (n=8) were tested. CONCLUSIONS: These findings highlight a missed opportunity to identify a treatable cause of hypertension in patients at high risk of recurrent cerebrovascular events. Routine testing for primary aldosteronism in stroke care pathways may improve long-term outcomes through targeted intervention.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 15
Improving diagnosis of primary aldosteronism through education: a modified Delphi study to identify key learning points
Background: Primary aldosteronism (PA) is the most common endocrine cause of secondary hypertension and can be effectively managed, or even cured, with targeted treatment. Despite this, it remains largely undiagnosed leaving a significant patient population with resistant hypertension and modifiable cardiovascular risk. Objective: To determine expert consensus on key information about PA that should ideally be taught to medical students as a step toward improving the detection of this common, underdiagnosed, and often easily treated condition. Design: The study employed a modified Delphi method which consisted of three rounds, the first of which contained an open-ended question about key areas that experts believe to be most important for inclusion in medical teaching resources and then progressing to assessment of individual versus group rankings of consensus items. Experts included both clinician-educator-researchers and patients with lived experience. Results: Nine critical knowledge areas in epidemiology, diagnostics, and pathophysiology were identified by the Delphi as consensus items, with the highest ranked being: “PA is common but often under-diagnosed – think about it with every hypertensive patient.” Conclusion: Experts reached a consensus, for the first time, on nine critical knowledge areas about PA that should be covered in medical education. Importantly, the consensus accounted for patients’ values and decisions. The results of this study could be used to assess medical student knowledge and their learning resources to facilitate curriculum development and medical resource updates to ensure the timely and accurate diagnosis of PA in hypertensive patients.
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 15
Open AccessImproving diagnosis of primary aldosteronism through education: a modified Delphi study to identify key learning points
Background: Primary aldosteronism (PA) is the most common endocrine cause of secondary hypertension and can be effectively managed, or even cured, with targeted treatment. Despite this, it remains largely undiagnosed leaving a significant patient population with resistant hypertension and modifiable cardiovascular risk. Objective: To determine expert consensus on key information about PA that should ideally be taught to medical students as a step toward improving the detection of this common, underdiagnosed, and often easily treated condition. Design: The study employed a modified Delphi method which consisted of three rounds, the first of which contained an open-ended question about key areas that experts believe to be most important for inclusion in medical teaching resources and then progressing to assessment of individual versus group rankings of consensus items. Experts included both clinician-educator-researchers and patients with lived experience. Results: Nine critical knowledge areas in epidemiology, diagnostics, and pathophysiology were identified by the Delphi as consensus items, with the highest ranked being: “PA is common but often under-diagnosed – think about it with every hypertensive patient.” Conclusion: Experts reached a consensus, for the first time, on nine critical knowledge areas about PA that should be covered in medical education. Importantly, the consensus accounted for patients’ values and decisions. The results of this study could be used to assess medical student knowledge and their learning resources to facilitate curriculum development and medical resource updates to ensure the timely and accurate diagnosis of PA in hypertensive patients.